Overview of bio–pharmaceutical ventures in the USA, EU and Japan: Proposal for fostering and promotion of Japanese venture companies

Shoichiro HAMANO*

Summary

The number of bio–venture companies in Japan reached 531 at the end of 2005. However, this is still far fewer than in the USA and EU. The number of Initial Public Offerings (IPOs) of bio–venture companies is only 13 in Japan, compared with 314 in the USA. Global competition is strong among bio–venture companies. Possible measures to improve this situation are as follows: 1. Increase the number of Drug Delivery System (DDS), pharmaceutical technology–based venture companies. 2. Set up bio–venture supporting committees in academic societies. 3. Set up a global business support center to reduce the burden on individual venture companies in promoting world–wide business.

Key words

Bio–venture, biotechnology, Drug Delivery System (DDS), Pharmaceutical technology, Initial Public Offering (IPO), Global business, proposal, supporting system, academic society, business support